The bill amends the prescription drug price transparency act in Minnesota, specifically targeting the reporting requirements for wholesale drug distributors. Starting January 1, 2024, these distributors will be required to submit detailed monthly information to the commissioner regarding prescription drugs that are subject to a notification to report. This includes data such as the number of units acquired and sold, total spending before rebates, and gross revenue generated from sales, all of which must be reported for the 12-month period preceding the notification.

Key changes in the bill include the insertion of the requirement for monthly reporting of various metrics related to prescription drugs, such as the number of units acquired and sold, total spending, and rebate amounts. This shift aims to enhance transparency in drug pricing and distribution, allowing for better oversight and understanding of the pharmaceutical market in Minnesota.